Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), filed a Form 4 on November 6, 2026, disclosing option exercises and open-market share sales across three trading days from November 4 through November 6, 2026, all executed under a Rule 10b5-1 trading plan.

Key Highlights

  • Three-day activity: Rubinstein exercised stock options and sold shares on November 4, 5, and 6, 2026, with 11,881 shares acquired via option exercise on each day at $12.14 per share.
  • Total shares disposed: 35,643 shares of common stock were sold across the three days at weighted average prices ranging from approximately $25.78 to $27.88.
  • Resulting ownership: Following all reported transactions, Rubinstein directly held 377,802 shares of common stock.
  • Remaining options: The stock option balance (right to buy at $12.14, expiring 03/04/2032) stood at 58,990 shares after the three exercise transactions.
  • 10b5-1 plan: According to the filing, all transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Rubinstein on November 18, 2025.
  • Options fully vested: The filing states that the exercised options are "fully vested and exercisable."

Rubinstein's Option Exercises and Sales at Adaptive Biotechnologies, November 4-6, 2026

According to the Form 4 filing, Julie Rubinstein, serving as President and COO of Adaptive Biotechnologies Corp, carried out a series of transactions over three consecutive trading days. On each day, Rubinstein exercised stock options covering 11,881 shares at an exercise price of $12.14 per share, with the options carrying an expiration date of March 4, 2032. The filing notes that these options were "fully vested and exercisable."

On November 4, 2026, the filing reports that Rubinstein sold 4,000 shares at a weighted average price of $25.78 (ranging from $25.26 to $26.22) and 7,881 shares at a weighted average price of $26.60 (ranging from $26.26 to $26.84). On November 5, 2026, sales totaled 11,881 shares in three separate tranches at weighted average prices of $26.10, $26.88, and $27.70, respectively. On November 6, 2026, an additional 11,881 shares were sold in two tranches at weighted average prices of $27.32 and $27.88. All reported prices are weighted averages, and the filing states that full per-share pricing information is available upon request to the company, its security holders, or SEC staff.

The filing states that all transactions were made pursuant to a Rule 10b5-1 trading plan that Rubinstein adopted on November 18, 2025. After all reported activity, Rubinstein's direct beneficial ownership of common stock stood at 377,802 shares, and the remaining stock option balance eligible for future exercise was reported as 58,990 shares.

What Was Disclosed

The Form 4 discloses option exercises and common stock sales by Adaptive Biotechnologies' President and COO, Julie Rubinstein, over November 4-6, 2026, conducted under a pre-established Rule 10b5-1 plan, leaving her with 377,802 directly held shares.